# Candesartan for Migraine Prevention:

> **NCT04574713** · PHASE2 · COMPLETED · sponsor: **St. Olavs Hospital** · enrollment: 450 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Candesartan Oral Tablet 8 mg
- **DRUG:** Candesartan Oral Tablet 16 mg
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04574713
- **Lead sponsor:** St. Olavs Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-09
- **Primary completion:** 2024-04-12
- **Final completion:** 2024-08-08
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04574713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04574713, "Candesartan for Migraine Prevention:". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04574713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*